Resveratrol Protects Against Doxorubicin-Induced Cardiotoxicity in Aged Hearts Through the SIRT1-USP7 Axis
Thomas K. Sin,Bjorn T. Tam,Benjamin Yat‐Ming Yung,Shea Ping Yip,Lawrence Chan,Sze Chuen Cesar Wong,Michael Ying,John A. Rudd,Parco M. Siu
DOI: https://doi.org/10.1113/jp270101
2015-01-01
The Journal of Physiology
Abstract:The Journal of PhysiologyVolume 593, Issue 8 p. 1887-1899 Research PaperFree Access Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis Thomas K. Sin, Thomas K. Sin Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorBjorn T. Tam, Bjorn T. Tam Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorBenjamin Y. Yung, Benjamin Y. Yung Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorShea P. Yip, Shea P. Yip Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorLawrence W. Chan, Lawrence W. Chan Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorCesar S. Wong, Cesar S. Wong Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorMichael Ying, Michael Ying Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorJohn A. Rudd, John A. Rudd School of Biomedical Science, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong, ChinaSearch for more papers by this authorParco M. Siu, Corresponding Author Parco M. Siu Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaCorresponding author P. M. Siu: Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Yuk Choi Road, Hung Hom, Kowloon, Hong Kong, China. Email: parco.siu@polyu.edu.hkSearch for more papers by this author Thomas K. Sin, Thomas K. Sin Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorBjorn T. Tam, Bjorn T. Tam Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorBenjamin Y. Yung, Benjamin Y. Yung Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorShea P. Yip, Shea P. Yip Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorLawrence W. Chan, Lawrence W. Chan Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorCesar S. Wong, Cesar S. Wong Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorMichael Ying, Michael Ying Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaSearch for more papers by this authorJohn A. Rudd, John A. Rudd School of Biomedical Science, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong, ChinaSearch for more papers by this authorParco M. Siu, Corresponding Author Parco M. Siu Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, ChinaCorresponding author P. M. Siu: Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Yuk Choi Road, Hung Hom, Kowloon, Hong Kong, China. Email: parco.siu@polyu.edu.hkSearch for more papers by this author First published: 09 February 2015 https://doi.org/10.1113/jphysiol.2014.270101Citations: 62AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Key points Doxorubicin induced functional deteriorations and elevations of USP7-related apoptotic/catabolic signalling in the senescent heart Resveratrol protects against doxorubicin-induced alterations through the restoration of SIRT1 deacetylase activity Abstract A compromised cardiac function is often seen in elderly cancer patients receiving doxorubicin therapy. The present study tested the hypothesis that acute intervention with resveratrol, a natural anti-oxidant found in grapes and red wine, reduces the cardiotoxicity of doxorubicin through restoration of sirtuin 1 (SIRT1) deacetylase activity, and attenuation of the catabolic/apoptotic pathways orchestrated by USP7, a p53 deubiquitinating protein, using young (aged 2 months) and old (aged 10 months) senescence-accelerated mice prone 8 (SAMP8). Animals were randomised to receive saline, doxorubicin, and doxorubicin in combination with resveratrol, in the presence or absence of SIRT1 inhibitors, sirtinol or EX527. Resveratrol alone, but not in combination with either of the SIRT1 inhibitors, suppressed the doxorubicin-induced impairment of cardiac systolic function in aged animals. Doxorubicin reduced SIRT1 deacetylase activity, and elevated proteasomal activity and USP7; it also increased the protein level of p300 and ubiquitinated proteins in hearts from aged SAMP8. These doxorubicin-induced alterations were prevented by resveratrol, whereas the protective action of resveratrol was antagonised by sirtinol and EX527. In young SAMP8 hearts, resveratrol attenuated the doxorubicin-induced increases in acetylation of Foxo1 and transactivation of MuRF-1, whereas these mitigations were not found after treatment with SIRT1 inhibitors. However, the protein contents of acetylated Foxo1 and MuRF-1 were not affected by any of the drugs studied in aged SAMP8 hearts. Resveratrol also ameliorated the augmentation of pro-apoptotic markers including p53, Bax, caspase 3 activity and apoptotic DNA fragmentation induced by doxorubicin in hearts from aged animals, whereas these reductions were diminished by combined treatment with SIRT1 inhibitors. These data demonstrate that resveratrol ameliorates doxorubicin-induced cardiotoxicity in aged hearts through the restoration of SIRT1 activity to attenuate USP7-related catabolic/pro-apoptotic signalling. Abbreviations AMPK AMP-activated protein kinase DR doxorubicin + resveratrol DRE doxorubicin + resveratrol + EX527 DRS doxorubicin + resveratrol + sirtinol DV doxorubicin and vehicle EF ejection fraction FS fractional shortening LVEDD left ventricle end-diastolic dimension LVESD left ventricle end-systolic dimension SAMP8 senescence-accelerated mice prone 8 SC saline control SIRT1 sirtuin 1 TBST Tris-buffered saline with 0.1% Tween 20 TUNEL terminal deoxynucleotidyl transferase dUTP nick end labelling Introduction Doxorubicin has been used clinically as an anti-cancer agent, although its use is known to be associated with cardiotoxicity. Studies have found an increase of mortality associated with the total accumulated dose of doxorubicin in chemotherapy cycles (Von Hoff et al. 1977). In particular, senior patients undergoing doxorubicin therapy have an additional risk of developing congestive heart failure (Von Hoff et al. 1977). Research has focussed on the design of doxorubicin analogues with reduced acute toxicity, although this has been confounded by a paralleled loss of anti-cancer efficacy (Weiss, 1992). Despite the fact that the 10-year survival of patients with doxorubicin-related cardiomyopathy was found to be pronounced after receiving heart transplantation (Lenneman et al. 2013), the co-administration of cardioprotective adjuvants may appear to represent a more effective approach for enhancing the therapeutic effects of doxorubicin. Resveratrol, a natural anti-oxidant commonly found in grapes, red wine and berries, is a small-molecule activator of the longevity-related gene sirtuin 1 (SIRT1) (Howitz et al. 2003). Studies show that resveratrol (10 mg kg−1) reduces cell proliferation and increases cell cycle arrest induced by doxorubicin in tumour-bearing mice, and also reduces pathohistological damage to the hearts of doxorubicin-treated albino rats (Osman et al. 2013). Pretreatment with resveratrol enhances SIRT1 activity, as indicated by a reduced acetylation of histone H3, which may alleviate oxidative stress (measured as carboxy-H2DCFDA) in doxorubicin-treated cardiomyocytes (Danz et al. 2009). These results are in agreement with studies showing that dietary supplementation with resveratrol (20 mg kg−1) reduces markers of oxidative damage, including malondialdehyde and 4-hydroxyalkenals, as well as cardiac inflammatory infiltration after exposure of the heart to doxorubicin (Dudka et al. 2012). Other compelling evidence suggests that resveratrol confers anti-apoptotic effects in other experimental models of doxorubicin-induced cardiotoxicity. Oral administration of resveratrol (20 mg kg−1 day−1) reduces the elevation of caspase 3 and fibrotic deposition in doxorubicin-exposed hearts (Arafa et al. 2014). Resveratrol (15 mg kg−1 day−1) also up-regulates SIRT1 and improves cardiac systolic function after doxorubicin exposure; there was also a concomitant reduction of the protein contents of acetylated p53 and Bax and the terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) index, suggesting that the intrinsic deacetylase activity may be involved in the mechanism of action of SIRT1 leading to the cardioprotective effects of resveratrol (Zhang et al. 2011). Other studies confirm that doxorubicin increases p53 and cleaved caspase 3 in cardiomyocytes, although these elevations were prevented by overexpression of AMP-activated protein kinase (AMPK), an activating signal of SIRT1 in mouse embryonic fibroblasts (Wang et al. 2012). Nonetheless, whether resveratrol would suppress apoptosis in the aged heart after doxorubicin treatment through the activation of SIRT1 deacetylase activity remains unknown. It is generally assumed that activation of the catabolic pathway contributes to myocardial toxicity induced by doxorubicin. Foxo1 is a member of the Forkhead-transcription factor family, which regulates the expression of apoptotic and atrophic genes. Proteomic profiling in H9c2 cardiomyocytes revealed that cathepsin B, a transcriptional target of Foxo1, was increased by doxorubicin (Bao et al. 2012). In other studies, short-term exercise was shown to prevent doxorubicin-induced elevation of mRNA levels of Foxo1 and MuRF-1, which are atrophic factors of the heart (Kavazis et al. 2014), whereas a reduction of SIRT1 and its deacetylase activity is associated with increased pro-apoptotic signalling in cardiomyocytes of patients with advanced heart failure (Lu et al. 2014) and in senescent mice (Sin et al. 2014). USP7 is a p53-deubiquitinating enzyme (Li et al. 2002) that affects the accumulation of p53 in human osteosarcoma cells (Fang & Luna, 2013). It has been reported that p53, HAUSP and polyubiquitinated proteins, and the proteasomal chymotrypsin-like activity and cleavage of caspase 3 are all elevated in the hearts of patients with dilated cardiomyopathy compared to non-failing hearts (Birks et al. 2008). Taken together, these findings suggest that apoptotic and catabolic pathways may act in concert to mediate doxorubicin-induced myocardial toxicity. In the present study, we investigated whether doxorubicin causes a functional deterioration of cardiac function in senescence-accelerated mice prone 8 (SAMP8) through the suppression of SIRT1 deacetylase activity and subsequent up-regulation of Foxo1/USP7-related catabolic/apoptotic axis, and also whether resveratrol can protect against the associated decrease of SIRT1 deacetylase activity. Methods Experimental animals Male SAMP8 were obtained from The Chinese University of Hong Kong. Animal husbandry was carried out as described previously (Sin et al. 2014). All experimental procedures were approved by the Animal Subjects Ethics Subcommittee of The Hong Kong Polytechnic University. Experimental design To investigate whether the cardioprotective effects of resveratrol is SIRT1-dependent, the present study used two commonly-adopted inhibitors of SIRT1: sirtinol and EX527. Mice aged 2 months (young) and 10 months (aged) were randomly assigned to receive saline control (SC), doxorubicin and vehicle (DV), doxorubicin + resveratrol (DR), or a combination of DR + sirtinol (DRS) or DR + EX527 (DRE) (Fig. 1). Figure 1. Schematic diagram illustrating the treatment protocol of SAMP8 of both age groupsOpen in figure viewerPowerPoint SAMP8 aged 2 months (young) and 10 months (aged) were randomly assigned to receive SC, DV, DR and DRS or DRE. On day 1, animals were injected i.p. with doxorubicin at 18 mg kg−1 (DV) (Zhu et al. 2010), except that the saline control group (SC) receiving the corresponding amount of saline. The DR, DRS and DRE groups were administered resveratrol (20 mg kg−1 day−1) from day 2 to day 4 (Oktem et al. 2012), whereas the SC and DV groups were injected with vehicle (95% DMSO), accordingly. In the DRS and DRE groups, 2 mg kg−1 day−1 sirtinol (Yang et al. 2013) and 5 mg kg−1 day−1 EX527 (based on our dose-optimisation experiments), respectively, were administered via the i.p. route immediately after all doses of resveratrol. On day 5, all mice were subject to non-invasive echocardiography and sacrificed using an overdose of ketamine (Alfasan, Woerden, The Netherlands). Left ventricular tissues were quickly dissected for further analysis. The treatment protocol is illustrated in Fig. 1. Non-invasive echocardiography Cardiac function was assessed by non-invasive echocardiography as described by the American Society of Echocardiography (Lang et al. 2006). Parameters, including left ventricle end-systolic dimension (LVESD), left ventricle end-diastolic dimension (LVEDD), anterior wall thickness, posterior wall thickness and heart rate, were measured under M-mode scanning with an Esaote MyLab 70 X-Vision Ultrasound System (Esaote, Genova, Italy). Systolic function measured as fractional shortening (FS) and ejection fraction (EF) was calculated by the equations for FS (%) = [(LVEDD – LVESD)/LVEDD] × 100 and EF (%) = Y + [(100 – Y) × 0.15], where Y = [(LVEDD2 – LVESD2)/LVEDD2] × 100. All results are reported as average values from three consecutive cardiac cycles. Western blotting Preparation of cytoplasmic protein extracts and the Bradford assay were performed as described previously (Sin et al. 2014). Briefly, 30 μg of protein was loaded on 10% polyacrylamide gels and separated by SDS-PAGE. The proteins were then transferred to PVDF membranes (Immobilon P; Millipore, Billerica, MA, USA) at 300 mA for 2 h in 1 × transfer buffer containing 10% methanol, except for p300, in which the 1 × transfer buffer contained 5% methanol. Equal loading and transfer efficiency were assured by Coomassie blue and Ponceau S red staining, respectively. The membranes were blocked in 5% non-fat milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h at room temperature followed by overnight incubation at 4°C with the corresponding primary antibodies in TBST with 2% bovine serum albumin (Table 1). The membranes were washed 3 times using TBST, followed by 1 h of incubation with the corresponding secondary antibodies at room temperature (Table 1). Luminol reagent (NEL103001EA; Perkin Elmer, Waltham, MA, USA) was applied and chemiluminescent signals were captured using a 4000R Pro camera (Eastman Kodak, Rochester, NY, USA). All data were normalised to the signal of β-tubulin. Table 1. Antibodies used in Western blotting Antibody Dilution factor Source SIRT1 rabbit polyclonal 1:500 sc15404; Santa Cruz Biotechnology (Santa Cruz, CA, USA) p300 rabbit polyclonal 1:100 sc584; Santa Cruz Biotechnology Ac-FKHR rabbit polyclonal 1:200 sc4943; Santa Cruz Biotechnology FKHR rabbit polyclonal 1:500 sc11350; Santa Cruz Biotechnology MAFbx rabbit polyclonal 1:200 sc33782; Santa Cruz Biotechnology MuRF-1 rabbit polyclonal 1:500 sc32920; Santa Cruz Biotechnology Ubiquitin mouse monoclonal 1:1000 3936; Cell Signaling (Beverly, MA, USA) USP7 rabbit polyclonal 1:800 101648; Abcam (Cambridge, MA, USA) p53 mouse monoclonal 1:200 sc56179; Santa Cruz Biotechnology Bax rabbit polyclonal 1:200 sc493; Santa Cruz Biotechnology β-tubulin mouse monoclonal 1:2000 T0198; Sigma-Aldrich (St Louis, MO, USA) Mouse IgG 1:3000 7076; Cell Signaling Rabbit IgG 1:3000 7074; Cell Signaling All antibodies used for Western blotting in the present study are listed in the order: origins of host, dilution factors and manufacturer. SIRT1 deacetylation assay Deacetylase activity of SIRT1 was assessed by a fluorometric method in accordance with the manufacturer's instructions (Cyclex, Nagoya, Japan). Each reaction was initiated by the addition of 5 μl of protease inhibitor-free cardiac protein extracts with thorough mixing. Fluorescence intensity was measured by a microplate fluorometer (Infinite F200; Tecan, Männedorf, Switzerland). All readings were normalised to the respective protein concentrations. Proteasome activity assay Proteasomal activity was measured based on the release of fluorescent 7-amino-4-methylcoumarin from 7-amino-4-methylcoumarin-tagged peptide substrate in the presence of proteolytic activity. All procedures were carried out in accordance with the manufacturer's instructions (K245-100; Biovision, Milpitas, CA, USA). Caspase 3 activity assay Protease activity of caspase 3 was assessed by a fluorometric approach involving the use of the caspase 3 substrate, DEVD-AFC (1007–200; Biovision). All procedures were the same as those described previously (Teng et al. 2011). Cell death enzyme-linked immunosorbent assay A cell death enzyme-linked immunosorbent assay (Roche Diagnostics, Indianapolis, IN, USA) was used to determine apoptotic DNA fragmentation in accordance with the manufacturer's instructions. Statistical analysis Statistical analyses were conducted using SPSS, version 21.0 (IBM Corp., Armonk, NY, USA). A normality test was performed to examine data distributions. All data are expressed as the mean ± SEM. Comparisons were made using one-way ANOVA followed by Tukey's post hoc tests. P < 0.05 was considered statistically significant. Results Cardiac systolic function Representative M-mode echocardiographic images of treatment groups are shown in Fig. 2A. Cardiac systolic functioning measured as FS and EF was 22% and 16% lower in aged compared to young SAMP8, respectively (Fig. 2B and C). Doxorubicin significantly reduced FS in both age groups, although the absolute percentage change observed in aged mice appeared to be less prominent (young DV vs. aged DV: 17% vs. 9%) (Fig. 2B); a similar pattern was observed with the EF parameter (young DV vs. aged DV: 12% vs. 9%) (Fig. 2C). Resveratrol attenuated significantly the doxorubicin-induced reductions of FS and EF in both age groups, whereas its cardioprotective effects were abolished by the co-administration of either of the SIRT1 inhibitors, sirtinol or EX527 (Fig. 2B and C). Except for LVESD, all other cardiac parameters were not significantly different among groups (Fig. 2D–H). Figure 2. Resveratrol attenuated the doxorubicin-induced impairment of cardiac function in aged SAMP8Open in figure viewerPowerPoint Non-invasive echocardiography was performed upon completion of the treatment protocol. Representative echocardiographic images are shown (A). FS (B) and EF (C) were calculated according to cardiac parameters including LVESD (D) and LVEDD (E). Anterior wall thickness (AWT), posterior wall thickness (PWT) and heart rate (HR) were also measured in all mice (F–H). *P < 0.05, doxorubicin effect; #P < 0.05, resveratrol effect; +P < 0.05, inhibitor effect; $P < 0.05, ageing effect. Mice were assigned to SC, DV, DR and DRS or DRE groups. SIRT1-p300-Foxo1 axis The protein level of SIRT1 was not significantly different in hearts obtained from both age groups and was not affected by drug treatment (Fig. 3A). Conversely, the heart deacetylase activity of SIRT1 was 21% lower in aged- compared to young-SAMP8 (Fig. 3B). Compared to saline-treated controls, the activity of SIRT1 in the heart was reduced significantly by 38% in young doxorubicin-treated SAMP8 and by 37% in aged doxorubicin-treated SAMP8 (Fig. 3B). Resveratrol antagonised significantly the reductions of SIRT1 activity induced by doxorubicin in hearts from both young and aged SAMP8 (Fig. 3B). Cardiac SIRT1 activity in mice co-treated with doxorubicin, resveratrol and sirtinol, or EX527, was not significantly different from their age-matched littermates treated with doxorubicin alone (Fig. 3B). The protein content of p300 acetylase was not significantly different between the hearts of saline-treated animals of young and aged SAMP8 (Fig. 3C). Doxorubicin elevated significantly the protein level of p300 by 98% and 52%, in hearts obtained from young and aged SAMP8, respectively, whereas these increases were antagonised by resveratrol (Fig. 3C). However, the resveratrol-induced reductions of p300 in both age groups were attenuated significantly by both SIRT1 inhibitors (Fig. 3C). In the saline controls, the acetylation status of Foxo1 was 118% higher in hearts from aged SAMP8 compared to young SAMP8 (Fig. 3D). Doxorubicin elevated significantly the protein content of acetylated Foxo1 by 102% in the hearts obtained from young SAMP8 (Fig. 3D). This doxorubicin-induced increase was blunted significantly by resveratrol alone but not by resveratrol in combination with sirtinol or EX527 (Fig. 3D). Acetylation of Foxo1 was not affected by any interventions in the hearts of aged SAMP8 (Fig. 3D). Figure 3. Doxorubicin-induced cardiotoxicity involved disruption of SIRT1 but not Foxo1Open in figure viewerPowerPoint The protein level of SIRT1 was not different among all groups. A, doxorubicin, but not in combination with resveratrol, reduced further the deacetylase activity of SIRT1 in the aged heart. B, the protein content of p300 was not affected by ageing but was elevated by doxorubicin in both groups. C, doxorubicin did not increase further the acetylation status of Foxo1 in the aged heart regardless of resveratrol treatment. D, *P < 0.05, doxorubicin effect; #P < 0.05, resveratrol effect; +P < 0.05, inhibitor effect; $P < 0.05, ageing effect. Mice were assigned to SC, DV, DR and DRS or DRE groups. Catabolic markers The protein expression of MAFbx was not significantly different among treatment or age groups (Fig. 4A). However, the protein level of MuRF-1 was 185% higher in hearts obtained from aged SAMP8 compared to young SAMP8 (Fig. 4B). Doxorubicin elevated significantly the MuRF-1 by 249% in the hearts of young SAMP8, and this increase was antagonised significantly by resveratrol alone but not when used in conjunction with sirtinol or EX527 (Fig. 4B). The protein level of MuRF-1 in the hearts of aged SAMP8 was not modified by any of the treatments (Fig. 4B). Basal protein ubiquitination was not different between hearts obtained from saline-treated young and aged SAMP8 (Fig. 4C). Doxorubicin elevated significantly the level of ubiquitinated proteins in the heart by 131% and 105% in young and aged SAMP8, respectively (Fig. 4C). These doxorubicin-induced increases were antagonised by resveratrol alone but not by resveratrol in combination with sirtinol or EX527 (Fig. 4C). Basal proteasomal activity and the protein level of USP7 were 105% and 85% higher in the hearts from aged SAMP8 compared to young SAMP8, respectively (Fig. 4D and E). In young SAMP8, proteasomal activity and the protein level of USP7 were significantly increased by 145% and 321%, respectively, in response to doxorubicin treatment; these elevations were significantly antagonised by resveratrol alone but not by resveratrol in combination with sirtinol or EX527 (Fig. 4D and E). Moreover, doxorubicin also elevated proteasomal activity and the protein level of USP7 in hearts obtained from aged SAMP8 by 110% and 417%, respectively (Fig. 4D and E); these changes were abolished by resveratrol alone but not by resveratrol in combination with sirtinol or EX527 (Fig. 4D and E). Figure 4. Resveratrol reduced the elevation of catabolic markers in doxorubicin-challenged aged heartsOpen in figure viewerPowerPoint The protein level of MAFbx was neither affected by age, nor any interventions. A, the protein abundance of MuRF-1 exhibited a similar changing pattern as acetylation of Foxo1. B, resveratrol mitigated the doxorubicin-induced elevation of protein ubiquitination in the heart of both age groups. C, augmentation of proteasomal activity (D) and protein content of USP7 (E) by doxorubicin in aged heart was blunted after resveratrol treatment. *P < 0.05, doxorubicin effect; #P < 0.05, resveratrol effect; +P < 0.05, inhibitor effect; $P < 0.05, ageing effect. Mice were assigned to SC, DV, DR and DRS or DRE groups. Apoptotic signalling The basal protein expression of pro-apoptotic factors p53 and Bax was significantly higher in hearts obtained from aged SAMP8 compared to young SAMP8, by 95% and 94%, respectively; the activity of caspase 3 and apoptotic DNA fragmentation were also 123% and 104% significantly higher, respectively, in hearts obtained from aged SAMP8 (Fig. 5). Doxorubicin significantly increased the levels of p53 and Bax, caspase 3 activity and apoptotic DNA fragmentation by 135%, 29%, 122% and 111%, respectively, in the hearts of young SAMP8 compared to their age-matched saline controls (Fig. 5). Doxorubicin also increased significantly the protein levels of p53 and Bax, caspase 3 activity and apoptotic DNA fragmentation in the aged heart by 13%, 28%, 38% and 157%, respectively; these elevations were antagonised by resveratrol (Fig. 5). Sirtinol and EX527 significantly reversed the suppression of all apoptotic markers induced by co-treatment with doxorubicin and resveratrol in both age groups (Fig. 5). Figure 5. Resveratrol reduced apoptotic activation in aged hearts in response to doxorubicin exposureOpen in figure viewerPowerPoint Resveratrol blunted the doxorubicin-induced augmentation of protein p53 (A) and Bax (B), caspase 3 activity (C), and apoptotic DNA fragmentation (D) in the aged heart. *P < 0.05, doxorubicin effect; #P < 0.05, resveratrol effect; +P < 0.05, inhibitor effect; $P < 0.05, ageing effect. Mice were assigned to SC, DV, DR and DRS or DRE groups. Discussion Cardioprotection by resveratrol requires SIRT1 Alteration of SIRT1 expression/activity has been implicated in various cardiac pathologies. The level of SIRT1 appears to be reduced in the left atrium of patients with advanced heart failure (Lu et al. 2014), whereas inhibition of SIRT1 by sirtinol was shown to reduce the improvement of cardiac contractility induced by resveratrol in a rat model of traumatic haemorrhage (Jian et al. 2012); sirtinol also blocks resveratrol-induced reductions of infarct size in mice exposed to ischaemia–reperfusion injury (Shalwala et al. 2014). These former studies support the hypothesis that SIRT1 is required to mediate the cardioprotective effects of resveratrol. Although the molecular mechanism of action underlying the attenuation of doxorubicin-induced cardiac contractile abnormalities including bradycardia and QTc interval prolongation in response to resveratrol administration remains to be identified (Rezk et al. 2006), these promising physiological outcomes could be attributable to the activation of SIRT1 deacetylase. Importantly, the present study shows that cardiac systolic function and SIRT1 deacetylase activity were reduced concomitantly in the aged heart, an observation consistent with our previous study (Sin et al. 2014), and we also provide new evidence showing that resveratrol prevents doxorubicin-induced cardiotoxicity in aged hearts through the restoration of SIRT1 deacetylase activity. Resveratrol inhibits catabolic machinery in a SIRT1-dependent manner A growing body of evidence suggests that doxorubicin-induced cardiotoxicity may involve activation of the catabolic pathway. It has been reported that doxorubicin prevents the accumulation of endogenous proteasomal substrates, c-Jun and β-catenin, in neonatal rat cardiomyocytes (Liu et al. 2008) and increased carbonylation and degradation of cardiac myosin binding protein C in HL-1 ca
What problem does this paper attempt to address?
-
Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury
Qingling Zhang,Yunpeng Zhang,Bingxin Xie,Daiqi Liu,Yueying Wang,Zandong Zhou,Yue Zhang,Emma King,Gary Tse,Tong Liu
DOI: https://doi.org/10.1002/cai2.64
2023-04-01
Cancer Innovation
Abstract:The Sirtuin1 agonist resveratrol could inhibit cardiomyocyte apoptosis by upregulating Mitofusin2, antagonizing oxidative stress injury, and ameliorating doxorubicin‐induced cardiotoxicity. Background Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different malignancies. However, its use is associated with dose‐dependent cardiotoxicity, causing irreversible myocardial damage and significantly reducing the patient's quality of life and survival. In this study, an animal model of doxorubicin‐induced cardiomyopathy was used to investigate the pathogenesis of doxorubicin‐induced myocardial injury. This study also investigated a possible treatment strategy for alleviating myocardial injury through resveratrol therapy in vitro. Methods Adult male C57BL/6J mice were randomly divided into a control group and a doxorubicin group. Body weight, echocardiography, surface electrocardiogram, and myocardial histomorphology were measured. The mechanisms of doxorubicin cardiotoxicity in H9c2 cell lines were explored by comparing three groups (phosphate‐buffered saline, doxorubicin, and doxorubicin with resveratrol). Results Compared to the control group, the doxorubicin group showed a lower body weight and higher systolic arterial pressure, associated with reduced left ventricular ejection fraction and left ventricular fractional shortening, prolonged PR interval, and QT interval. These abnormalities were associated with vacuolation and increased disorder in the mitochondria of cardiomyocytes, increased protein expression levels of α‐smooth muscle actin and caspase 3, and reduced protein expression levels of Mitofusin2 (MFN2) and Sirtuin1 (SIRT1). Compared to the doxorubicin group, doxorubicin + resveratrol treatment reduced caspase 3 and manganese superoxide dismutase, and increased MFN2 and SIRT1 expression levels. Conclusion Doxorubicin toxicity leads to abnormal mitochondrial morphology and dysfunction in cardiomyocytes and induces apoptosis by interfering with mitochondrial fusion. Resveratrol ameliorates doxorubicin‐induced cardiotoxicity by activating SIRT1/MFN2 to improve mitochondria function.
-
Modulating Effect of SIRT1 Activation Induced by Resveratrol on Foxo1‐associated Apoptotic Signalling in Senescent Heart
Thomas K. Sin,Angus P. Yu,Benjamin Y. Yung,Shea Ping Yip,Lawrence W. Chan,Cesar S. Wong,Michael Ying,John A. Rudd,Parco M. Siu
DOI: https://doi.org/10.1113/jphysiol.2014.271387
2014-01-01
The Journal of Physiology
Abstract:Key points Cardiac function is impaired and Foxo1/Bim‐related apoptotic signalling is up‐regulated in senescent heart Activation of SIRT1 deacetylase activity by resveratrol attenuates the Foxo1/Bim signalling axis in senescent heart AbstractElevations of cardiomyocyte apoptosis and fibrotic deposition are major characteristics of the ageing heart. Resveratrol, a polyphenol in grapes and red wine, is known to improve insulin resistance and increase mitochondrial biogenesis through the SIRT1–PGC‐1α signalling axis. Recent studies attempted to relate SIRT1 activation by resveratrol to the regulation of apoptosis in various disease models of cardiac muscle. In the present study, we tested the hypothesis that long‐term (8‐month) treatment of resveratrol would activate SIRT1 and improve the cardiac function of senescent mice through suppression of Foxo1‐associated pro‐apoptotic signalling. Our echocardiographic measurements indicated that the cardiac systolic function measured as fractional shortening and ejection fraction was significantly reduced in aged mice when compared with the young mice. These reductions, however, were not observed in resveratrol‐treated hearts. Ageing significantly reduced the deacetylase activity, but not the protein abundance of SIRT1 in the heart. This reduction was accompanied by increased acetylation of the Foxo1 transcription factor and transactivation of its target, pro‐apoptotic Bim. Subsequent analyses indicated that pro‐apoptotic signalling measured as p53, Bax and apoptotic DNA fragmentation was up‐regulated in the heart of aged mice. In contrast, resveratrol restored SIRT1 activity and suppressed elevations of Foxo1 acetylation, Bim and pro‐apoptotic signalling in the aged heart. In parallel, resveratrol also attenuated the ageing‐induced elevations of fibrotic collagen deposition and markers of oxidative damage including 4HNE and nitrotyrosine. In conclusion, these novel data demonstrate that resveratrol mitigates pro‐apoptotic signalling in senescent heart through a deacetylation mechanism of SIRT1 that represses the Foxo1–Bim‐associated pro‐apoptotic signalling axis.
-
Resveratrol Protects Against Doxorubicin-Induced Cardiotoxicity by Attenuating Ferroptosis Through Modulating the MAPK Signaling Pathway.
Lu Chen,Xingang Sun,Zhen Wang,Miao Chen,Yuxian He,Han Zhang,Deheng Han,Liangrong Zheng
DOI: https://doi.org/10.1016/j.taap.2023.116794
IF: 4.46
2024-01-01
Toxicology and Applied Pharmacology
Abstract:Doxorubicin (Dox) is a widely used antitumor agent with dose-dependent and cumulative cardiotoxic effects. Resveratrol (Res) is a natural non-flavonoid polyphenol that can potentially provide cardiovascular benefits. We aimed to estimate the protective effect of Res on Dox-induced cardiotoxicity (DIC) and explore whether it was related to attenuating ferroptosis. We established DIC models in C57BL/6 J mice, H9C2 cardiomyoblasts, and neonatal rat cardiomyocytes (NRCMs). We further treated H9C2 cells with RSL3, a ferroptosis agonist, to investigate whether Res exerted protective effects through inhibiting ferroptosis. Ferrostatin-1 (Fer-1) was applied to suppress ferroptosis. Dox treatment caused cardiac dysfunction and resulted in apparent ferroptotic damage in cardiac tissue, involving increased iron accumulation, glutathione depletion, increased expression of ferroptosis-related proteins, and decreased expression of glutathione peroxidase 4, which were alleviated by Fer-1 and Res administration. These findings were also confirmed in Dox-treated H9C2 cells and NRCMs, with Fer-1 and Res effectively attenuating Dox-induced cytotoxicity and ferroptosis. Furthermore, Res protected H9C2 cells from RSL3-induced ferroptotic cell death, and the protective effect was similar to that of Fer-1. Both Dox and RSL3 treatment increased the phosphorylation levels of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinases; however, these changes were hindered by Res. This study demonstrates that Res effectively alleviates DIC by suppressing ferroptosis possibly through modulating the MAPK signaling pathway. Our results highlight that targeting ferroptosis can be a potential cardioprotective strategy for DIC.
-
SIRT1 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the Oxidative Stress and P38mapk Pathways
Yang Ruan,Chunlin Dong,Jigar Patel,Chao Duan,Xinyue Wang,Xi Wu,Yuan Cao,Lianmei Pu,Dan Lu,Tao Shen,Jian Li
DOI: https://doi.org/10.1159/000373937
2015-01-01
Cellular Physiology and Biochemistry
Abstract:Background: SIRT1, which belongs to the Sirtuin family of NAD-dependent enzymes, plays diverse roles in aging, metabolism, and disease biology. It could regulate cell survival and has been shown to be a protective factor in heart function. Hence, we verified the mechanism by which SIRT1 regulates doxorubicin induced cardiomyocyte injury in vivo and in vitro. Methods: We analyzed SIRT1 expression in doxorubicin-induced neonatal rat cardiomyocyte injury model and adult mouse heart failure model. SIRT1 was over-expressed in cultured neonatal rat cardiomyocyte by adenovirus mediated gene transfer. SIRT1 agonist resveratrol was used to treat the doxorubicin-induced heart failure mouse model. Echocardiography, reactive oxygen species (ROS) production, TUNEL, qRT-PCR, and Western blotting were performed to analyze cell survival, oxidative stress, and inflammatory signal pathways in cardiomyocytes. Results: SIRT1 expression was down-regulated in doxorubicin induced cardiomocyte injury, accompanied by elevated oxidative stress and cell apoptosis. SIRT1 over-expression reduced doxorubicin induced cardiomyocyte apoptosis with the attenuated ROS production. SIRT1 also reduced cell apoptosis by inhibition of p38MAPK phosphorylation and caspase-3 activation. The SIRT1 agonist resveratrol was able to prevent doxorubicin-induced heart function loss. Moreover, the SIRT1 inhibitor niacinamide could reverse SIRT1's protective effect in cultured neonatal rat cardiomyocytes. Conclusions: These results support the role of SIRT1 as an important regulator of cardiomyocyte apoptosis during doxorubicin-induced heart injury, which may represent a potential therapeutic target for doxorubicin-induced cardiomyopathy.
-
SIRT6 activates PPARα to improve doxorubicin-induced myocardial cell aging and damage
Shulin Wang,Xuan Zhang,Yanhong Hou,Yuliang Zhang,Jiamin Chen,Shuhan Gao,Huiying Duan,Shaoju Gu,Shanshan Yu,Yi Cai
DOI: https://doi.org/10.1016/j.cbi.2024.110920
IF: 5.168
2024-04-01
Chemico-Biological Interactions
Abstract:The Sirtuins family, formally known as the Silent Information Regulator Factors, constitutes a highly conserved group of histone deacetylases. Recent studies have illuminated SIRT6's role in doxorubicin (DOX)-induced oxidative stress and apoptosis within myocardial cells. Nevertheless, the extent of SIRT6's impact on DOX-triggered myocardial cell aging and damage remains uncertain, with the associated mechanisms yet to be fully understood. In our research, we examined the influence of SIRT6 on DOX-induced cardiomyocyte senescence using β-galactosidase and γ-H2AX staining. Additionally, we gauged the mRNA expression of senescence-associated genes, namely p16, p21, and p53, through Real-time PCR. Employing ELISA assay kits, MDA, and total SOD activity assay kits, we measured inflammatory factors TNF-α, IL-6, and IL-1β, alongside oxidative stress-related indicators. The results unequivocally indicated that SIRT6 overexpression robustly inhibited DOX-induced cardiomyocyte senescence. Furthermore, we established that SIRT6 overexpression suppressed the inflammatory response and oxidative stress induced by DOX in cardiomyocytes. Conversely, silencing SIRT6 exacerbated DOX-induced cardiomyocyte injury. Our investigations further unveiled that SIRT6 upregulated the expression of genes CD36, CPT1, LCAD, MCAD associated with fatty acid oxidation through its interaction with PPARα, thereby exerting anti-aging effects. In vivo, the overexpression of SIRT6 was observed to restore DOX-induced declines in EF and FS to normal levels in mice. Echocardiography and HE staining revealed the restoration of cardiomyocyte alignment, affording protection against DOX-induced myocardial senescence and injury. The findings from this study suggest that SIRT6 holds significant promise as a therapeutic target for mitigating DOX-induced cardiomyopathy.
pharmacology & pharmacy,biochemistry & molecular biology,toxicology
-
Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction
Paula K N Alves,André Cruz,Volker Adams,Anselmo S Moriscot,Siegfried Labeit
DOI: https://doi.org/10.1016/j.ejphar.2024.177027
2024-12-05
Abstract:Cancer chemotherapy induces cell stress in rapidly dividing cancer cells to trigger their growth arrest and apoptosis. However, adverse effects related to cardiotoxicity underpinned by a limited regenerative potential of the heart limits clinical application: In particular, chemotherapy with doxorubicin (DOXO) causes acute heart injury that can transition to persisting cardiomyopathy (DOXO-CM). Here, we tested if MuRF1 inhibition ("MuRFi") was able to attenuate DOXO-CM. To mimic DOXO chemotherapy, we treated mice over four weeks with five DOXO injections, resulting in a cumulative dosage of 25 mg/kg. At day 28, mice had lower body and heart weights, reduced cardiac cross-sectional myofibrillar areas (CSAs), and disturbed functional ejection fractions (EFs) and fractional shortenings (FS) as indicated by echocardiography (ECHO). In contrast, mice with a 1 g/kg Myomed#205 spiked diet, a previously described experimental MuRFi therapy, showed lower DOXO-CM at day 28, and also reduced acute DOXO cardiac injury at day 7 (single DOXO dose; 15 mg/kg). Underlying molecular signatures using Western blot (WB) assays showed at day 28 reduced phospho-AKT (AKTp) and phospo-4EBP1 (4 EBP1p) levels following DOXO that were normalized following MuRFi treatment. Taken together, our data suggest that MuRFi treatment is suitable to attenuate DOXO-CM by preserving AKTp and 4 EBP1p levels in DOXO stressed cardiomyocytes, thereby supporting de novo protein translation and cardiomyocyte survival under translational arrest stress.
-
Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury
Chao Tong,Alex Morrison,D. Paul Thomas,Ji Li
IF: 37.8
2011-01-01
Circulation
Abstract:Background: Aging is associated with a reduced tolerance to myocardial ischemia/reperfusion (I/R) injury. SIRT1, a putative anti-aging protein, is thought to be a potential interventional target for age-related ischemic heart disease due to its ability to attenuate the age-dependent decline in cardiac function. We hypothesized that SIRT1 is involved in the intolerance of the aged heart to ischemic stress. Methods and Results: 4-6 months-old (young) and 24-26 months-old (aged) male C57BL/6 mice, 4-6 months-old male Sirt1 +/- heterozygous knockout and Sirt1 +/+ wild type littermates mice were used. The results show that SIRT1 is predominantly localized in the nuclei of cardiomyocytes, and SIRT1 protein levels in the aged hearts are significantly lower than those in young hearts; a similar discrepancy was also found between Sirt1 +/- and Sirt1 +/+ hearts (n=4-6, p p p in vivo . Moreover, after 20 min of LAD coronary ligation followed by 4 hrs of reperfusion, myocardial infarction size in aged and Sirt1 +/- hearts is markedly higher than in young and Sirt1 +/+ hearts (45% and 31%, respectively, all p Sirt1 +/- hearts to 8% and 7%, respectively (all p p vs. vehicle). Conclusions: Increased susceptibility of the aged heart to I/R injury is largely attributed to impaired cardiac SIRT1 activity, and pharmacological SIRT1 activation can restore tolernace of aged heart to ischemic insults. Therefore, modulating SIRT1 activity may be a beneficial therapeutic strategy for the elderly with acute coronary syndromes.
-
Resveratrol Prevents Doxorubicin-Induced Cardiotoxicity in H9c2 Cells Through the Inhibition of Endoplasmic Reticulum Stress and the Activation of the Sirt1 Pathway.
Yu Lou,Zhen Wang,Yi Xu,Ping Zhou,Junxian Cao,Yuanshi Li,Yeping Chen,Junfeng Sun,Lu Fu
DOI: https://doi.org/10.3892/ijmm.2015.2291
IF: 5.314
2015-01-01
International Journal of Molecular Medicine
Abstract:Treatment with doxorubicin (DOX) is one of the major causes of chemotherapy-induced cardiotoxicity and is therefore, the principal limiting factor in the effectiveness of chemotherapy for cancer patients. DOX‑induced heart failure is thought to result from endoplasmic reticulum (ER) stress and cardiomyocyte apoptosis. Resveratrol (RV), a polyphenol antioxidant found in red wine, has been shown to play a cardioprotective role. The aim of the present study was to examine the effects of RV on DOX‑induced cardiotoxicity in H9c2 cells. We hypothesized that RV would protect H9c2 cells against DOX‑induced ER stress and subsequent cell death through the activation of the Sirt1 pathway. Our results demonstrated that the decrease observed in the viability of the H9c2 cells following exposure to DOX was accompanied by a significant increase in the expression of the ER stress‑related proteins, glucose‑regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP). However, we found that RV downregulated the expression of ER stress marker protein in the presence of DOX and restored the viability of the H9c2 cells. Exposure to RV or DOX alone only slightly increased the protein expression of Sirt1, whereas a significant increase in Sirt1 protein levels was observed in the cells treated with both RV and DOX. The Sirt1 inhibitor, nicotinamide (NIC), partially neutralized the effects of RV on the expression of Sirt1 in the DOX‑treated cells and completely abolished the effects of RV on the expression of GRP78 and CHOP. The findings of our study suggest that RV protects H9c2 cells against DOX‑induced ER stress through ER stabilization, and more specifically through the activation of the Sirt1 pathway, thereby leading to cardiac cell survival.
-
Mitochondrial Sirtuin-3 (SIRT3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress
Mateusz M. TomczykKyle G. CheungBo XiangNahid TamannaAna L. Fonseca TeixeiraPrasoon AgarwalStephanie M. KereliukVictor SpicerLigen LinJason TrebergQiang TongVernon W. DolinskyDiabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme of the Children's Hospital Research Institute of Manitoba' Winnipeg' Canada (M.M.T.,K.G.C.,B.X.,P.A.,S.M.K.,V.W.D.).Department of Pharmacology and Therapeutics,University of Manitoba,Winnipeg,Canada. (M.M.T.,K.G.C.,B.X.,P.A.,S.M.K.,V.W.D.)Department of Internal Medicine,University of Manitoba,Winnipeg,Canada. (V.S.)Rady Faculty of Health Science,College of Medicine,University of Manitoba,Winnipeg,Canada. (M.M.T.,K.G.C.,B.X.,P.A.,S.M.K.,V.S.,V.W.D.)Department of Biological Sciences,University of Manitoba,Winnipeg,Canada. (N.T.,A.L.F.T.,J.T.)Manitoba Center for Proteomics and Systems Biology,Winnipeg,Canada (V.S.).Children's Nutrition Research Center,Baylor College of Medicine,Houston,TX (L.L.,Q.T.).KTH Royal Institute of Technology,School of Electrical Engineering and Computer Science,Stockholm,Sweden (P.A.).Science for Life Laboratory,Solna,Sweden (P.A.).Institute of Chinese Medical Sciences,University of Macau,China (L.L.).
DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008547
2022-04-16
Abstract:High doses of doxorubicin put cancer patients at risk for developing dilated cardiomyopathy. Previously, we showed that doxorubicin treatment decreases SIRT3 (sirtuin 3), the main mitochondrial deacetylase and increases protein acetylation in rat cardiomyocytes. Here, we hypothesize that SIRT3 expression can attenuate doxorubicin induced dilated cardiomyopathy in vivo by preventing the acetylation of mitochondrial proteins. Nontransgenic, M3-SIRT3 (truncated SIRT3; short isoform), and M1-SIRT3 (full-length SIRT3; mitochondrial localized) transgenic mice were treated with doxorubicin for 4 weeks (8 mg/kg body weight per week). Echocardiography was performed to assess cardiac structure and function and validated by immunohistochemistry and immunofluorescence (n=4–10). Mass spectrometry was performed on cardiac mitochondrial peptides in saline (n=6) and doxorubicin (n=5) treated hearts. Validation was performed in doxorubicin treated primary rat and human induced stem cell derived cardiomyocytes transduced with adenoviruses for M3-SIRT3 and M1-SIRT3 and deacetylase deficient mutants (n=4–10). Echocardiography revealed that M3-SIRT3 transgenic mice were partially resistant to doxorubicin induced changes to cardiac structure and function whereas M1-SIRT3 expression prevented cardiac remodeling and dysfunction. In doxorubicin hearts, 37 unique acetylation sites on mitochondrial proteins were altered. Pathway analysis revealed these proteins are involved in energy production, fatty acid metabolism, and oxidative stress resistance. Increased M1-SIRT3 expression in primary rat and human cardiomyocytes attenuated doxorubicin-induced superoxide formation, whereas deacetylase deficient mutants were unable to prevent oxidative stress. Doxorubicin reduced SIRT3 expression and markedly affected the cardiac mitochondrial acetylome. Increased M1-SIRT3 expression in vivo prevented doxorubicin-induced cardiac dysfunction, suggesting that SIRT3 could be a potential therapeutic target for mitigating doxorubicin-induced dilated cardiomyopathy.
-
Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity
Xuan Zhang,Chaoming Huang,Yanhong Hou,Shisheng Jiang,Yu Zhang,Shulin Wang,Jiamin Chen,Jianmei Lai,Lifeng Wu,Huiying Duan,Shuwen He,Xinyi Liu,Shanshan Yu,Yi Cai
DOI: https://doi.org/10.1016/j.phymed.2024.155673
IF: 6.656
2024-04-28
Phytomedicine
Abstract:Background Doxorubicin (DOX) is a widely utilized anthracycline chemotherapy drug in cancer treatment, yet its efficacy is hindered by both short-term and long-term cardiotoxicity. Although oxidative stress, inflammation and mitochondrial dysfunction are established factors in DOX-induced cardiotoxicity, the precise molecular pathways remain elusive. Further exploration of the pathogenesis and identification of novel molecular targets are imperative. Recent studies have implicated the Sirtuins family in various physiological and pathological processes, suggesting their potential in ameliorating DOX-induced cardiotoxicity. Moreover, research on Sirtuins has discovered small-molecule compounds or medicinal plants with regulatory effects, representing a notable advancement in preventing and treating DOX-induced cardiac injury. Purpose In this review, we delve into the pathogenesis of DOX-induced cardiotoxicity and explore the therapeutic effects of Sirtuins in mitigating this condition, along with the associated molecular mechanisms. Furthermore, we delineate the roles and mechanisms of small-molecule regulators of Sirtuins in the prevention and treatment of DOX-induced cardiotoxicity. Study-design/methods Data for this review were sourced from various scientific databases (such as Web of Science, PubMed and Science Direct) up to March 2024. Search terms included "Sirtuins," "DOX-induced cardiotoxicity," "DOX," "Sirtuins regulators," "histone deacetylation," among others, as well as several combinations thereof. Results Members of the Sirtuins family regulate both the onset and progression of DOX-induced cardiotoxicity through anti-inflammatory, antioxidative stress and anti-apoptotic mechanisms, as well as by maintaining mitochondrial stability. Moreover, natural plant-derived active compounds such as Resveratrol (RES), curcumin, berberine, along with synthetic small-molecule compounds like EX527, modulate the expression and activity of Sirtuins. Conclusion The therapeutic role of the Sirtuins family in mitigating DOX-induced cardiotoxicity represents a potential molecular target. However, further research is urgently needed to elucidate the relevant molecular mechanisms and to assess the safety and biological activity of Sirtuins regulators. This review offers an in-depth understanding of the therapeutic role of the Sirtuins family in mitigating DOX-induced cardiotoxicity, providing a preliminary basis for the clinical application of Sirtuins regulators in this condition.
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
-
Modulation of the Sirtuin-1 signaling pathway in doxorubicin-induced nephrotoxicity (synergistic amelioration by resveratrol and pirfenidone)
Samia Mahmoud manway,Eman Mohamed Faruk,Rabab fawzy hindawy,Mahmoud M Hassan,Diaa M.G. Farrag,Mansour A.E. Bashar,Hanan Fouad,Rania Abubaker Bagabir,Dina Allam Abdelmaksoud Hassan,Ahmed Mohammed Zaazaa,Mohamed Ghazy Attia Hablas,Kamal Mostafa Kamal,Samia Mahmoud Manawy,Rabab Fawzy Hindawy,Mahmoud M. Hassan,K Mostafa Kamal
DOI: https://doi.org/10.1016/j.tice.2024.102330
IF: 2.586
2024-02-28
Tissue and Cell
Abstract:The current study was conducted to determine the precise mechanisms of Sirtuin-1 (Sirt-1), TGF- β (Transforming Growth Factor-β), and long non-coding RNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (LncRNA MALAT-1) in signaling pathways in doxorubicin (DOX)-induced nephrotoxicity. The potential therapeutic effect of Resveratrol and Pirfenidone in DOX toxicity was also assessed. Thirty-six male adult rats were evenly distributed into four groups: Group 1: control rats. Group 2: DOX exposed rats' group, each animal received 7.5 mg/kg DOX as a single intravenous dose, Group 3: DOX exposed group subjected to oral resveratrol (20 mg/kg/daily for two weeks), Group 4: DOX exposed group subjected to oral Pirfenidone (200 mg/kg once daily for 10 days). At the planned time, animals were sacrificed. Renal tissue was collected to assess matrix metalloproteinase-9 (MMP9), inflammatory and apoptotic markers: tumor necrosis factor-alpha (TNF- β, caspase-3, cyclo-oxygenase-2 (COX-2), and oxidative stress markers: nitric oxide (NO), Glutathione (GSH), malondialdehyde (MDA), and superoxide dismutase (SOD). Sirtuin-1 (Sirt-1), TGF-β, and LncRNA MALAT-1 were quantitatively assessed by real-time RT-PCR in the whole blood. Results showed that the DOX group exhibited a significant increase in oxidative stress markers, and inflammatory, and apoptotic markers in the renal tissue. Histologically, the renal tubule lining cells exhibited vacuolar alterations in the cytoplasm, glomerular atrophy, and vascular congestion. Furthermore, renal degeneration was evident, as confirmed by the heightened immuno-expression of MMP9. Exposure to DOX resulted in a significant decrease in Sirtuin-1 (Sirt-1) with a significant increase in the TGFβ, and LncRNA MALAT-1 gene expression. However, pre-treatment with either resveratrol/or Pirefenidone ameliorated the histological renal alterations, regulated the pathways of Sirt-1, TGFβ, and LncRNA MALAT-1, and decreased all oxidative stress, inflammatory and apoptotic markers. In conclusion, DOX exposure leads to renal toxicity by inducing renal degeneration, oxidative stress, and apoptosis. Administration of either resveratrol or Pirfenidone counteracted these changes and protected the kidney against DOX-induced renal damage.
cell biology,anatomy & morphology
-
USP14 modulates cell pyroptosis and ameliorates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing SIRT3
Zhiming Zhang,Binwei Jin,Yang Zhang,Minjun Yang,Cheng Wang,Yu Zhu,Tao Li,Jiangbo Lin,Mengqi Yang,Ying Cheng,Shasha Xu,Kui He,Jiayi Xu,Yafei Mi,Jianjun Jiang,Zhenzhu Sun
DOI: https://doi.org/10.1016/j.freeradbiomed.2024.10.302
2024-10-28
Abstract:This study investigates the role of the deubiquitinating enzyme USP14 in alleviating doxorubicin (DOX)-induced cardiotoxicity (DIC), particularly concerning its mechanism of regulating pyroptosis through the stabilization of the mitochondrial protein SIRT3. Using in vivo and in vitro models, the research demonstrated that USP14 overexpression protects against DOX-induced cardiac damage by modulating pyroptosis. Silencing SIRT3 via siRNA revealed that SIRT3 is a key intermediary molecule in USP14-mediated regulation of pyroptosis. Notably, DOX exposure resulted in decreased USP14 expression, while its overexpression preserved mitochondrial function and reduced oxidative stress by stabilizing SIRT3. Immunoprecipitation confirmed that USP14 stabilizes SIRT3 through deubiquitination. These findings position USP14 as a promising therapeutic target for mitigating DOX-induced cardiotoxicity by stabilizing SIRT3 and maintaining mitochondrial integrity, suggesting potential novel strategies for cardio-protection in chemotherapy.
-
Effects of long-term resveratrol-induced SIRT1 activation on insulin and apoptotic signalling in aged skeletal muscle
Thomas K. Sin,Angus P. Yu,Benjamin Y. Yung,Shea P. Yip,Lawrence W. Chan,Cesar S. Wong,John A. Rudd,Parco M. Siu
DOI: https://doi.org/10.1007/s00592-015-0767-3
2015-01-01
Acta Diabetologica
Abstract:Aims Activation of Foxo1 is known to promote apoptosis and disturbances to insulin signalling. However, their modulating roles in aged skeletal muscle are not clear. The present study tested the hypothesis that long-term (i.e. 8 month) resveratrol supplementation would improve physical traits including exercise capacity and basal voluntary activity of aged mice and modulate insulin/apoptotic signalling in aged skeletal muscle. This study also examined whether these resveratrol-associated alterations would involve orchestration of the SIRT1–Foxo1 signalling axis. Methods Two-month-old SAMP8 mice were randomly assigned to young, aged and aged with resveratrol treatment (AR) groups. The AR mice were supplemented with 4.9 mg −1 kg −1 day −1 resveratrol for 8 months. All animals were subject to endurance capacity test and voluntary motor behaviour assessment. The lateral gastrocnemius muscle tissues were harvested for further analyses. Results Long-term resveratrol treatment significantly alleviated the age-associated reductions in exercise capacity and voluntary motor behaviour. The protein content, but not the deacetylase activity of SIRT1 was increased with concomitant elevations of p300 acetylase and acetylation of Foxo1 in aged muscle. The aged muscle also manifested signs of impaired insulin signalling including attenuated phosphorylation of Akt, activity of pyruvate dehydrogenase and membrane trafficking of GLUT4 and elevated levels of phosphorylated IRS1 and iNOS and apoptotic activation measured as Bim, p53 and apoptotic DNA fragmentation. Intriguingly, all these age-related adverse changes were mitigated with the activation of SIRT1 deacetylase activity after long-term resveratrol treatment. Conclusions These data suggest that modulation of the SIRT1–Foxo1 axis by long-term resveratrol treatment enhances physical traits and alleviates the unfavourable changes in insulin and apoptotic signalling in aged muscle.
-
Effects of resveratrol on tolerance to ischemia/reperfusion injury in aged male mice: Role of autophagy and apoptosis
Xiaogang Song,Chao Wei,Hui Huang,Xingdan Cao,Ziyi Chen,Yongqing Chen,Bing Wu
DOI: https://doi.org/10.1002/fsn3.3525
2023-06-28
Abstract:Aged myocardium is more susceptible to ischemia/reperfusion (I/R) injury. Autophagy and apoptosis play important roles in cardiac I/R injury. However, whether resveratrol can reduce the I/R vulnerability of aged myocardium by regulating apoptosis and autophagy remains unclear. The present study aimed to investigate the effect of resveratrol on the tolerance to I/R injury in aged male mice and to determine the contribution of apoptosis and autophagy. We used aged C57 mice as our research subjects. The hearts of mice were isolated after 6 weeks of intragastric administration with resveratrol and subsequently perfused with Krebs-Henseleit buffer to produce the I/R model. We found that resveratrol alleviated cardiac I/R injury in aged mice, but not in SIRT1+/- mice. Aged mice exhibited decreased LC3 and Beclin1 expressions, which were significantly rescued by resveratrol treatment. In addition, resveratrol decreased the expression of Bax and the activity of Caspase-3, while increasing the expression of Bcl-2 and the activity of SIRT1 in aged mouse hearts. Coimmunoprecipitation assays revealed that resveratrol facilitated the binding of Bax to Bcl-2 and the dissociation of Bcl-2 from Beclin1 in aged mouse myocardium. Conversely, SIRT1 knockout enhanced the formation of the Beclin1/Bcl-2 complex and disrupted the interaction between Bcl-2 and Bax. The above results indicate that resveratrol can reduce the vulnerability of myocardial I/R injury in senile myocardium by inhibiting apoptosis and upregulating autophagy through the SIRT1 signaling pathway.
-
Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling
Kezheng Peng,Chenye Zeng,Yuqi Gao,Binliang Liu,Liyuan Li,Kang Xu,Yuemiao Yin,Ying Qiu,Mingkui Zhang,Fei Ma,Zhao Wang
DOI: https://doi.org/10.1016/j.apsb.2023.03.019
IF: 14.903
2023-03-01
Acta Pharmaceutica Sinica B
Abstract:Since the utilization of anthracyclines in cancer therapy, severe cardiotoxicity has become a major obstacle. The major challenge in treating cancer patients with anthracyclines is minimizing cardiotoxicity without compromising antitumor efficacy. Herein, histone deacetylase SIRT6 expression was reduced in plasma of patients treated with anthracyclines-based chemotherapy regimens. Furthermore, overexpression of SIRT6 alleviated doxorubicin-induced cytotoxicity in cardiomyocytes, and potentiated cytotoxicity of doxorubicin in multiple cancer cell lines. Moreover, SIRT6 overexpression ameliorated doxorubicin-induced cardiotoxicity and potentiated antitumor efficacy of doxorubicin in mice, suggesting that SIRT6 overexpression could be an adjunctive therapeutic strategy during doxorubicin treatment. Mechanistically, doxorubicin-impaired mitochondria led to decreased mitochondrial respiration and ATP production. And SIRT6 enhanced mitochondrial biogenesis and mitophagy by deacetylating and inhibiting Sgk1. Thus, SIRT6 overexpression coordinated metabolic remodeling from glycolysis to mitochondrial respiration during doxorubicin treatment, which was more conducive to cardiomyocyte metabolism, thus protecting cardiomyocytes but not cancer cells against doxorubicin-induced energy deficiency. In addition, ellagic acid, a natural compound that activates SIRT6, alleviated doxorubicin-induced cardiotoxicity and enhanced doxorubicin-mediated tumor regression in tumor-bearing mice. These findings provide a preclinical rationale for preventing cardiotoxicity by activating SIRT6 in cancer patients undergoing chemotherapy, but also advancing the understanding of the crucial role of SIRT6 in mitochondrial homeostasis.
pharmacology & pharmacy
-
Redd1 knockdown prevents doxorubicin-induced cardiac senescence
Pianpian Huang,Lijuan Bai,Lihua Liu,Jun Fu,Kefei Wu,Hongxia Liu,Yun Liu,Benming Qi,Benling Qi
DOI: https://doi.org/10.18632/aging.202972
2021-05-06
Abstract:Regulated in development and DNA damage response-1 (Redd1) is a stress-response gene that is transcriptionally induced by diverse stressful stimuli to influence cellular growth and survival. Although evidence suggests that aging may drive Redd1 expression in skeletal muscles, the expression patterns and functions of Redd1 in senescent cardiomyocytes remain unspecified. To address this issue, in vitro and in vivo models of cardiomyocyte senescence were established by administration of doxorubicin (Dox). Redd1 overexpression and knockdown was achieved in cultured H9c2 cardiomyocytes and mouse tissues using, respectively, lentivirals and adeno-associated virus 9 (AAV9) vectors. In the hearts of both aged (24 months old) and Dox-treated mice, as well as in Dox-exposed H9c2 cardiomyocytes, high Redd1 expression accompanied the increase in both cellular senescence markers (p16INK4a and p21) and pro-inflammatory cytokine expression indicative of a stress-associated secretory phenotype (SASP). Notably, Redd1 overexpression accentuated, whereas Redd1 silencing markedly attenuated, Dox-induced cardiomyocyte senescence features both in vitro and in vivo. Notably, AAV9-shRNA-mediated Redd1 silencing significantly alleviated Dox-induced cardiac dysfunction. Moreover, through pharmacological inhibition, immunofluorescence, and western blotting, signaling pathway analyses indicated that Redd1 promotes cardiomyocyte senescence as a downstream effector of p38 MAPK to promote NF-kB signaling via p65 phosphorylation and nuclear translocation.
-
The modulation of SIRT1 and SIRT3 by natural compounds as a therapeutic target in doxorubicin‐induced cardiotoxicity: A review
Fatemeh B. Tabrizi,Fatemeh Yarmohammadi,A. Wallace Hayes,Gholamreza Karimi
DOI: https://doi.org/10.1002/jbt.22946
IF: 3.568
2021-11-08
Journal of Biochemical and Molecular Toxicology
Abstract:Doxorubicin (DOX) is a potent antitumor agent with a broad spectrum of activity; however, irreversible cardiotoxicity resulting from DOX treatment is a major issue that limits its therapeutic use. Sirtuins (SIRTs) play an essential role in several physiological and pathological processes including oxidative stress, apoptosis, and inflammation. It has been reported that SIRT1 and SIRT3 can act as a protective molecular against DOX-induced myocardial injury through targeting numerous signaling pathways. Several natural compounds (NCs), such as resveratrol, sesamin, and berberine, with antioxidative, anti-inflammation, and antiapoptotic effects were evaluated for their potential to suppress the cardiotoxicity induced by DOX via targeting SIRT1 and SIRT3. Numerous NCs exerted their therapeutic effects on DOX-mediated cardiac damage via targeting different signaling pathways, including SIRT1/LKB1/AMPK, SIRT1/PGC-1α, SIRT1/NLRP3, and SIRT3/FoxO. SIRT3 also ameliorates cardiotoxicity by enhancing mitochondrial fusion.
biochemistry & molecular biology,toxicology
-
Liposomal Resveratrol and/or Carvedilol Attenuate Doxorubicin-Induced Cardiotoxicity by Modulating Inflammation, Oxidative Stress and S100A1 in Rats
Abeer M. Alanazi,Laila Fadda,Ahlam Alhusaini,Rehab Ahmad,Iman H. Hasan,Ayman M. Mahmoud
DOI: https://doi.org/10.3390/antiox9020159
IF: 7.675
2020-02-16
Antioxidants
Abstract:Doxorubicin (DOX) is a cytotoxic anthracycline antibiotic and one of the important chemotherapeutic agents for different types of cancers. DOX treatment is associated with adverse effects, particularly cardiac dysfunction. This study examined the cardioprotective effects of carvedilol (CAR) and/or resveratrol (RES) and liposomal RES (LIPO-RES) against DOX-induced cardiomyopathy, pointing to their modulatory effect on oxidative stress, inflammation, S100A1 and sarco/endoplasmic reticulum calcium ATPase2a (SERCA2a). Rats received CAR (30 mg/kg) and/or RES (20 mg/kg) or LIPO-RES (20 mg/kg) for 6 weeks and were challenged with DOX (2 mg/kg) twice per week from week 2 to week 6. DOX-administered rats exhibited a significant increase in serum creatine kinase-MB (CK-MB), troponin-I and lactate dehydrogenase (LDH) along with histological alterations, reflecting cardiac cell injury. Cardiac toll-like receptor 4 (TLR-4), inducible nitric oxide synthase (iNOS), tumor necrosis factor (TNF)-α and interleukin (IL)-6 protein expression were up-regulated, and lipid peroxidation was increased in DOX-administered rats. Treatment with CAR, RES or LIPO-RES as well as their alternative combinations ameliorated all observed biochemical and histological alterations with the most potent effect exerted by CAR/LIPO-RES. All treatments increased cardiac antioxidants, and the expression of S100A1 and SERCA2a. In conclusion, the present study conferred new evidence on the protective effects of CAR and its combination with either RES or LIPO-RES on DOX-induced inflammation, oxidative stress and calcium dysregulation.
-
Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity
Wenzheng Xia,Hanbin Chen,Han Yang,Liaoxiang Zhu,Congying Xie,Meng Hou
DOI: https://doi.org/10.1111/febs.17164
2024-06-12
FEBS Journal
Abstract:A subset of cardiomyocytes acquires a senescence‐associated secretory phenotype (SASP) when subjected to doxorubicin (Dox). SASP cardiomyocytes affect healthy non‐senescent cardiomyocytes, rendering them senescent through delivery of exosomes. Clearance of senescent cardiomyocytes using the Bcl‐2 inhibitor ABT‐199 alleviates senescence of cardiomyocytes and prevents chemotherapy‐related cardiotoxicity. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐related cardiotoxicity and could be a new therapeutic target for Dox‐induced cardiac injury. Doxorubicin (Dox), an anthracycline antibiotic, is widely used in cancer treatment. Although its antitumor efficacy appears significant, its clinical use is greatly restricted by its induction of cardiotoxicity. Cardiac senescence drives the Dox‐induced cardiotoxicity, but whether diminishing these senescent cardiomyocytes could alleviate the cardiotoxicity remains unclear. Here, we assessed whether senescent cardiomyocytes have a senescence‐associated secretory phenotype (SASP) that affects healthy non‐senescent cardiomyocytes, rendering them senescent via the delivery of exosomes. Additionally, we explored whether targeting SASP senescent cardiomyocytes using a Bcl‐2 inhibitor could alleviate cardiotoxicity. Cardiac damage was induced in a mouse model of continuous Dox treatment in vivo, and cardiomyocytes in vitro. Immunofluorescence of the senescence markers of Cdkn2a, Cdkn1a and γ‐H2A.X was used to assess the SASP in the Dox‐treated heart. To explore the molecular mechanisms involved, the Bcl‐2 inhibitor ABT‐199 was employed to eliminate SASP senescent cardiomyocytes. We show that the cardiomyocytes acquire a SASP during Dox treatment. The senescent cardiomyocytes upregulated Bcl‐2, although treatment of mice with ABT‐199 selectively eliminated SASP senescent cardiomyocytes involved in Dox‐induced cardiotoxicity, thus leading to partial alleviation of Dox‐induced cardiotoxicity. Moreover, we concluded that SASP factors secreted by senescent cardiomyocytes induced by Dox renders otherwise healthy cardiomyocytes senescent through exosome delivery. Our findings suggest that SASP senescent cardiomyocytes are a significant component of the pathogenesis of Dox‐dependent cardiotoxicity and indicate that targeting the clearance of SASP senescent cardiomyocytes could be a new therapeutic approach for Dox‐induced cardiac injury.
biochemistry & molecular biology
-
Cardiac sirtuin1 deficiency exacerbates ferroptosis in doxorubicin-induced cardiac injury through the Nrf2/Keap1 pathway
Weiqi Wang,Xin Zhong,Zimin Fang,Jianmin Li,Hebo Li,Xuesheng Liu,Xindi Yuan,Weijian Huang,Zhouqing Huang
DOI: https://doi.org/10.1016/j.cbi.2023.110469
2023-05-25
Abstract:Doxorubicin (DOX), a broad-spectrum chemotherapeutic agent for various cancers, has limited clinical application because of its serious cardiotoxicity, which is due to different mechanisms, including cardiac ferroptosis and oxidative stress. Some drugs, such as berberine or dioscin, show efficacy in impeding DOX-induced cardiotoxicity by activating Sirtuin 1 (Sirt1). However, there is no direct evidence to clarify the role of Sirt1 in DOX-induced cardiomyopathy and its underlying role in cardiac ferroptosis. In this study, C57BL/6 and cardiac-specific Sirt1-/- knockout mice were used as a DOX-induced cardiotoxicity model. We found that cardiac Sirt1 was downregulated, oxidative stress was increased and ferroptosis were obviously enhanced, as reflected by decreased Glutathione peroxidase 4 (GPX4) and increased Heme oxygenase 1 (Hmox-1), exposure to DOX treatment in mice and H9c2 cells compared with the control. And Sirt1 activation was resistant to cardiac injury induced by DOX, as observed the improvement of cardiac dysfunction, and the reduction of cardiac fibrosis. However, cardiac Sirt1 deficiency aggravated Dox-induced cardiac dysfunction and cardiac remodeling, further downregulated GPX4, upregulated Hmox-1 expression and increased ROS level. In addition, Sirt1-siRNA exacerbated DOX-induced cardiotoxicity in H9c2 cells, which is similar to the results obtained in vivo. Furthermore, DOX decrease Nrf2 translocation from the cytosol to the nucleus, and Sirt1 deficiency further restrain the process, as well as the downstream Keap1 pathways, in DOX-induced cardiotoxicity. This study provides direct evidence that Sirt1 plays a protective role in DOX-induced cardiotoxicity by mediating ferroptosis reduction via the Nrf2/Keap1 pathway.